Neurogen Corporation Report issue

For profit Phase 2
Founded: Branford CT United States (1987)
Status: Acquired by Ligand Pharmaceuticals (2009)

Organization Overview

First Clinical Trial
2008
NCT00683436
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (3)

adipiplon (1 trial)

palindore (2 trials)

zolpidem (ambien) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 2)

Psychomotor Agitation (Phase 2)

Restless Legs Syndrome (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3